MANNKIND CORP
NASDAQ: MNKD (MannKind Corporation)
Kemas kini terakhir: 20 jam lalu3.95
-0.11 (-2.71%)
| Penutupan Terdahulu | 4.06 |
| Jumlah Dagangan | 1,984,111 |
| Harga / Pendapatan (P/E Ke hadapan) | 116.28 |
| Harga / Jualan (P/S) | 3.22 |
| Julat 52 Minggu |
| Margin Keuntungan | 10.12% |
| Margin Operasi (TTM) | 31.65% |
| EPS Cair (TTM) | 0.100 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 23.80% |
| Nisbah Semasa (MRQ) | 2.36 |
| Aliran Tunai Operasi (OCF TTM) | 29.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 39.45 M |
| Pulangan Atas Aset (ROA TTM) | 10.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | MannKind Corporation | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 5.0 |
| Purata | 1.00 |
|
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.86% |
| % Dimiliki oleh Institusi | 58.64% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| 180 Wealth Advisors, Llc | 30 Jun 2026 | 4,959,351 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |